NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Reflux Esophagitis; Erosive Esophagitis; Gastroesophageal Reflux Disease

Treatments: Drug: esomeprazole magnesium (oral medication)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00206180

D9612L00062

Details and patient eligibility

About

The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or non-pregnant, non-lactating female patients between the ages of 18 and 75 years
• Patients must have moderate to severe erosive esophagitis

Exclusion criteria

• Significant gastrointestinal bleeding
• Severe heart, lung, liver or kidney disease
• Esophagitis not related to acid reflux